USD 46.8 billion
PD-1 and PD-L1 Inhibitors Market Size, Share, Growth Analysis, By Product (Nivolumab, Pembrolizumab), By Indication (Melanoma, Non-Small Cell Lung Cancer (NSCLC)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies), By Region - Industry Forecast 2025-2032
Report ID:
SQMIG35I2102 |
Region:
Global |
Published Date: December, 2024
Pages:
157
|Tables:
89
|Figures:
76
PD-1 And PD-L1 Inhibitors Market Insights
PD-1 And PD-L1 Inhibitors Market size was valued at USD 41.83 Billion in 2023 and is poised to grow from USD 49.15 Billion in 2024 to USD 178.58 Billion by 2032, growing at a CAGR of 17.50% during the forecast period (2025-2032).
PD-1/PD-L1 inhibitors are a class of drugs that have revolutionized cancer treatment in recent years. PD-1 (programmed cell death protein 1) and PD-L1 (programmed cell death ligand 1) are two proteins that play a crucial role in regulating the immune system's response to cancer cells. When cancer cells develop, they often produce PD-L1, which binds to PD-1 on the surface of T cells and inhibits their activity. This is an immune evasion mechanism that allows cancer cells to evade the immune system's attack. PD-1/PD-L1 inhibitors work by blocking the interaction between PD-1 and PD-L1, which allows T cells to recognize and attack cancer cells. By unleashing the immune system's natural ability to fight cancer, PD-1/PD-L1 inhibitors have shown remarkable efficacy in a wide range of cancers, including lung cancer, melanoma, bladder cancer, and more. The first PD-1 inhibitor, pembrolizumab (Keytruda), was approved by the FDA in 2014 for the treatment of advanced melanoma. Since then, several other PD-1/PD-L1 inhibitors have been developed and approved for various cancer types, including nivolumab (Opdivo), atezolizumab (Tecentriq), durvalumab (Imfinzi), and avelumab (Bavencio).
The market has witnessed significant growth in recent years, owing to the increasing prevalence of cancer, rising awareness about immunotherapy, and the growing number of approvals for PD-1/PD-L1 inhibitor drugs by regulatory agencies. In addition, the development of combination therapies, which use PD-1/PD-L1 inhibitors in combination with other drugs, has further propelled the growth of the market. North America currently dominates the global PD-1/PD-L1 inhibitors market, owing to the high prevalence of cancer in the region, favorable reimbursement policies, and the presence of a well-established healthcare infrastructure. However, the market is expected to witness significant growth in Asia-Pacific in the coming years, owing to the growing awareness about immunotherapy and the increasing adoption of PD-1/PD-L1 inhibitors in the region. The key players in the global PD-1/PD-L1 inhibitors market include Bristol-Myers Squibb Company, Merck & Co., Inc., Roche Holding AG, AstraZeneca plc, Pfizer Inc., and Novartis AG, among others. These companies are focusing on developing new PD-1/PD-L1 inhibitor drugs, expanding their geographical presence, and entering into partnerships and collaborations to enhance their market position.
However, the high cost of PD-1/PD-L1 inhibitor drugs and the associated adverse effects may hinder the growth of the market to some extent. Moreover, the emergence of new immunotherapies and the increasing focus on personalized medicine may pose a challenge to the growth of the market.
US PD-1 And PD-L1 Inhibitors Market is poised to grow at a sustainable CAGR for the next forecast year.
Market snapshot - 2024-2031
Global Market Size
Largest Segment
PD-1 inhibitor
Fastest Growth
PD-1 inhibitor
Growth Rate
17.9% CAGR
Global PD-1 And PD-L1 Inhibitors Market 2022-2030 ($ Bn)
Country Share for North America Region- 2022 (%)
To get more reports on the above market click here to Buy The Report
PD-1 And PD-L1 Inhibitors Market Segmental Analysis
Global PD-1 And PD-L1 Inhibitors Market is segmented by product, indication, distribution channel and region. Based on product, the market is segmented into nivolumab, pembrolizumab, atezolizumab, avelumab and durvalumab. Based on indication, the market is segmented into melanoma, non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), head and neck squamous cell cancer (HNSCC), bladder cancer, merkel cell carcinoma (MCC) and others. Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies and online pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
PD-1 And PD-L1 Inhibitors Market Analysis by Type
PD-L1 inhibitors segment dominated the global market. PD-L1 inhibitors target the PD-L1 protein that is expressed on the surface of cancer cells. PD-L1 inhibitors work by blocking the interaction between PD-L1 and its receptor, which is found on T-cells. This releases the brakes on the immune system, allowing T-cells to recognize and attack cancer cells. The PD-L1 inhibitors segment is also witnessing significant growth, owing to the increasing number of approvals for PD-L1 inhibitors by regulatory agencies. Key PD-L1 inhibitors include Tecentriq (atezolizumab), Imfinzi (durvalumab), and Bavencio (avelumab). These drugs have been approved for the treatment of various types of cancer, including bladder cancer, non-small cell lung cancer, and Merkel cell carcinoma, among others
The PD-1 protein segment is expected to grow at the fastest CAGR. The PD-1 protein helps to regulate the immune response by preventing T-cells from attacking healthy cells in the body. Cancer cells can sometimes take advantage of this mechanism by expressing high levels of PD-L1, a protein that binds to PD-1 and inhibits T-cell activity. PD-1 inhibitors block the interaction between PD-1 and PD-L1, thereby allowing T-cells to attack cancer cells. The PD-1 inhibitors segment currently dominates the global PD-1/PD-L1 inhibitors market, owing to the high efficacy and safety profile of PD-1 inhibitors in the treatment of various types of cancer. Key PD-1 inhibitors include Opdivo (nivolumab), Keytruda (pembrolizumab), and Libtayo (cemiplimab). These drugs have been approved for the treatment of many types of cancers.
PD-1 And PD-L1 Inhibitors Market Analysis by End-User
By end-users, the market is segmented into hospitals, clinics, and others. Hospitals currently hold the largest share of the market, owing to the availability of advanced healthcare infrastructure, highly trained medical professionals, and the ability to provide comprehensive cancer care. Hospitals also have the necessary resources to conduct clinical trials and research studies, which are essential for the development of new PD-1/PD-L1 inhibitor drugs.
Clinics segment is expected to grow at the fastest CAGR. These are important end-user segment of the market, as they provide specialized cancer care to patients. Clinics may also offer personalized treatment plans that take into account the patient's individual needs and medical history. The growing trend of outpatient care has led to an increase in the number of clinics, which is expected to further drive the growth of this segment.
Global PD-1 And PD-L1 Inhibitors Market By Type, 2022 (%)
To get detailed analysis on other segments, Request For Free Sample Report
PD-1 And PD-L1 Inhibitors Market Regional Insights
North America is one of the largest markets for PD-1 and PD-L1 inhibitors, and it is expected to dominate the global market during the forecast period. The region's dominance can be attributed to various factors such as the high prevalence of cancer and autoimmune diseases, the presence of key market players, and favorable reimbursement policies. In North America, the United States holds the largest share of the PD-1 and PD-L1 inhibitors market, owing to the high prevalence of cancer and autoimmune diseases in the country. According to the American Cancer Society, it is estimated that in 2022, there will be around 1.9 million new cancer cases and over 609,000 cancer deaths in the United States. The rising incidence of cancer in the country is expected to drive the demand for PD-1 and PD-L1 inhibitors. Moreover, the presence of key market players in the region is also expected to drive the growth of the PD-1 and PD-L1 inhibitors market. Some of the major players in the market, such as Bristol-Myers Squibb, Merck & Co., and Pfizer, have their headquarters in the United States. These players are investing heavily in research and development activities to develop innovative PD-1 and PD-L1 inhibitors for the treatment of various diseases. Additionally, favorable reimbursement policies in the region are also expected to drive the growth of the market. The Affordable Care Act (ACA) in the United States has made it mandatory for insurers to cover cancer treatment costs, including PD-1 and PD-L1 inhibitors, which has increased patient access to these drugs.
On the other hand, Asia-Pacific (APAC) is expected to be the fastest growing region in the global PD-1/PD-L1 inhibitors market, owing to the increasing prevalence of cancer in the region and the growing adoption of immunotherapy. The region has a large population, which has led to a high burden of cancer, particularly in countries such as China, Japan, and South Korea. In addition, the region has witnessed significant investments in healthcare infrastructure, which has further propelled the growth of the market. Governments in the region have also implemented favorable policies to promote the adoption of immunotherapy, such as the inclusion of PD-1/PD-L1 inhibitors in the national healthcare reimbursement schemes. Moreover, the increasing focus on research and development activities, particularly in countries such as China and India, is expected to further drive the growth of the market. These countries have large populations and significant resources, which has led to the emergence of a strong research and development ecosystem. Key players in the market are also focusing on expanding their presence in the region by entering into partnerships and collaborations with local companies. For instance, Bristol-Myers Squibb entered into a collaboration with China's CSPC Pharmaceutical Group Limited to develop and commercialize its PD-1 inhibitor drug in China.
Global PD-1 And PD-L1 Inhibitors Market By Geography, 2022-2030
- Largest
- Fastest
To know more about the market opportunities by region and country, click here to
Buy The Complete Report
PD-1 And PD-L1 Inhibitors Market Dynamics
PD-1 And PD-L1 Inhibitors Market Drivers
Rising prevalence of cancer
- The increasing incidence of cancer globally is a significant driver of the PD-1 and PD-L1 inhibitors market. Cancer is the second biggest cause of mortality worldwide, with a projected 12 million deaths in 2022, according to the World Health Organization (WHO). PD-1 and PD-L1 inhibitors have shown significant efficacy in treating various types of cancer, such as lung cancer, melanoma, and bladder cancer. The rising prevalence of cancer, coupled with the growing demand for effective treatment options, is expected to drive the growth of the PD-1 and PD-L1 inhibitors market.
Development of advanced technologies
- The development of advanced technologies such as immuno-oncology and precision medicine is expected to drive the growth of the PD-1 and PD-L1 inhibitors market. These technologies have enabled researchers to develop innovative PD-1 and PD-L1 inhibitors that can target specific types of cancer and patients. Moreover, the use of biomarkers to identify patients who are most likely to respond to PD-1 and PD-L1 inhibitors is also expected to drive the growth of the market. These technological advancements have increased the efficacy and safety of PD-1 and PD-L1 inhibitors, thereby driving the growth of the market.
PD-1 And PD-L1 Inhibitors Market Restraints
Increasing Cost of Drug
- One of the main restraints of the PD-1/PD-L1 inhibitors market is the high cost of these drugs. PD-1/PD-L1 inhibitors are generally expensive, and the high cost may limit their accessibility to patients, particularly in developing countries. In addition, the associated adverse effects of these drugs, such as fatigue, nausea, and diarrhoea, may also limit their use. This may lead to a preference for conventional chemotherapy or other treatment options, which are often less expensive. The high cost of these drugs may also lead to a significant financial burden on healthcare systems and insurance providers, which may limit their willingness to cover the cost of these drugs.
Request Free Customization of this report to help us to meet your business objectives.
PD-1 And PD-L1 Inhibitors Market Competitive Landscape
Global PD-1 and PD-L1 inhibitors market is highly fragmented, with the presence of several small and large players. The market is characterized by intense competition, with players focusing on research and development activities to develop innovative products. Some of the key strategies adopted by players in the market include collaborations, partnerships, and mergers and acquisitions. Additionally, players are also focusing on expanding their product portfolios to cater to a wider range of diseases. The intense competition in the market is expected to drive the growth of the PD-1 and PD-L1 inhibitors market, with players striving to gain a larger share of the market.
PD-1 And PD-L1 Inhibitors Market Top Player’s Company Profiles
- Akeso Inc.
- Alphamab Oncology
- Amgen Inc.
- AstraZeneca Plc
- BeiGene Ltd.
- Bristol Myers Squibb Co.
- Chia Tai Tianqing Pharmaceutical Group Co. Ltd.
- Eli Lilly and Co.
- F. Hoffmann La Roche Ltd.
- Gilead Sciences Inc.
- GlaxoSmithKline Plc
- Innovent Biologics Inc.
- Jiangsu Hengrui Pharmaceuticals Co. Ltd.
- Merck and Co. Inc.
PD-1 And PD-L1 Inhibitors Market Recent Developments
- In January 2023, Bristol-Myers Squibb announced positive results from a phase III trial of its PD-1 inhibitor Opdivo in combination with chemotherapy for the treatment of patients with advanced or metastatic gastric or gastroesophageal junction cancer.
- In February 2022, Merck received FDA approval for Keytruda in combination with chemotherapy for the treatment of patients with advanced or metastatic gastric or gastroesophageal junction adenocarcinoma.
- In November 2021, Roche received FDA approval for its PD-L1 inhibitor Tecentriq (atezolizumab) for the treatment of patients with metastatic non-small cell lung cancer who have high PD-L1 expression.
- In September 2021, AstraZeneca announced positive results from a phase III trial of its PD-L1 inhibitor Imfinzi (durvalumab) in combination with chemotherapy for the treatment of small cell lung cancer.
- In June 2021, Merck announced positive results from a phase III trial of its PD-1 inhibitor Keytruda in combination with chemotherapy for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma.
PD-1 And PD-L1 Inhibitors Key Market Trends
- One key market trend in the global PD-1/PD-L1 inhibitors market is the increasing focus on combination therapies. There is growing evidence that combining PD-1/PD-L1 inhibitors with other drugs, such as chemotherapy or other immunotherapies, can improve their effectiveness and reduce the risk of resistance. Key players in the market are investing heavily in the development of combination therapies, and several new combination regimens are currently being tested in clinical trials. This trend is expected to continue in the coming years, as researchers and clinicians seek to improve patient outcomes and address the limitations of PD-1/PD-L1 inhibitors as monotherapies.
PD-1 And PD-L1 Inhibitors Market SkyQuest Analysis
SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our Business Information Services team that Collects, Collates, Co-relates, and Analyses the Data collected by means of Primary Exploratory Research backed by robust Secondary Desk research.
According to our Global PD-1 and PD-L1 inhibitors market analysis, the market is projected to experience significant growth over the forecast period, driven by several factors such as rising prevalence of cancer, technological advancements, and increasing demand for effective treatment options. The cancer segment is expected to dominate the market, owing to the increasing incidence of various types of cancer globally. North America is expected to dominate the market, owing to the high adoption rate of advanced technologies, favorable government initiatives, and the presence of a well-established healthcare infrastructure. However, Asia Pacific is projected to experience significant growth over the forecast period, driven by increasing government initiatives to improve healthcare infrastructure and the rising prevalence of cancer in the region.
| Report Metric | Details |
|---|---|
| Market size value in 2022 | USD 46.8 billion |
| Market size value in 2031 | USD 206.0 billion |
| Growth Rate | 17.9% |
| Base year | 2023 |
| Forecast period | 2024-2031 |
| Forecast Unit (Value) | USD Billion |
| Segments covered |
|
| Regions covered | North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA) |
| Companies covered |
|
| Customization scope | Free report customization with purchase. Customization includes:-
|
To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.
Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share
Table Of Content
Executive Summary
Market overview
- Exhibit: Executive Summary – Chart on Market Overview
- Exhibit: Executive Summary – Data Table on Market Overview
- Exhibit: Executive Summary – Chart on PD-1 And PD-L1 Inhibitors Market Characteristics
- Exhibit: Executive Summary – Chart on Market by Geography
- Exhibit: Executive Summary – Chart on Market Segmentation
- Exhibit: Executive Summary – Chart on Incremental Growth
- Exhibit: Executive Summary – Data Table on Incremental Growth
- Exhibit: Executive Summary – Chart on Vendor Market Positioning
Parent Market Analysis
Market overview
Market size
- Market Dynamics
- Exhibit: Impact analysis of DROC, 2021
- Drivers
- Opportunities
- Restraints
- Challenges
- Exhibit: Impact analysis of DROC, 2021
- SWOT Analysis
KEY MARKET INSIGHTS
- Technology Analysis
- (Exhibit: Data Table: Name of technology and details)
- Pricing Analysis
- (Exhibit: Data Table: Name of technology and pricing details)
- Supply Chain Analysis
- (Exhibit: Detailed Supply Chain Presentation)
- Value Chain Analysis
- (Exhibit: Detailed Value Chain Presentation)
- Ecosystem Of the Market
- Exhibit: Parent Market Ecosystem Market Analysis
- Exhibit: Market Characteristics of Parent Market
- IP Analysis
- (Exhibit: Data Table: Name of product/technology, patents filed, inventor/company name, acquiring firm)
- Trade Analysis
- (Exhibit: Data Table: Import and Export data details)
- Startup Analysis
- (Exhibit: Data Table: Emerging startups details)
- Raw Material Analysis
- (Exhibit: Data Table: Mapping of key raw materials)
- Innovation Matrix
- (Exhibit: Positioning Matrix: Mapping of new and existing technologies)
- Pipeline product Analysis
- (Exhibit: Data Table: Name of companies and pipeline products, regional mapping)
- Macroeconomic Indicators
COVID IMPACT
- Introduction
- Impact On Economy—scenario Assessment
- Exhibit: Data on GDP - Year-over-year growth 2016-2022 (%)
- Revised Market Size
- Exhibit: Data Table on PD-1 And PD-L1 Inhibitors Market size and forecast 2021-2027 ($ million)
- Impact Of COVID On Key Segments
- Exhibit: Data Table on Segment Market size and forecast 2021-2027 ($ million)
- COVID Strategies By Company
- Exhibit: Analysis on key strategies adopted by companies
MARKET DYNAMICS & OUTLOOK
- Market Dynamics
- Exhibit: Impact analysis of DROC, 2021
- Drivers
- Opportunities
- Restraints
- Challenges
- Exhibit: Impact analysis of DROC, 2021
- Regulatory Landscape
- Exhibit: Data Table on regulation from different region
- SWOT Analysis
- Porters Analysis
- Competitive rivalry
- Exhibit: Competitive rivalry Impact of key factors, 2021
- Threat of substitute products
- Exhibit: Threat of Substitute Products Impact of key factors, 2021
- Bargaining power of buyers
- Exhibit: buyers bargaining power Impact of key factors, 2021
- Threat of new entrants
- Exhibit: Threat of new entrants Impact of key factors, 2021
- Bargaining power of suppliers
- Exhibit: Threat of suppliers bargaining power Impact of key factors, 2021
- Competitive rivalry
- Skyquest special insights on future disruptions
- Political Impact
- Economic impact
- Social Impact
- Technical Impact
- Environmental Impact
- Legal Impact
Market Size by Region
- Chart on Market share by geography 2021-2027 (%)
- Data Table on Market share by geography 2021-2027(%)
- North America
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- USA
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Canada
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Europe
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- Germany
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Spain
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- France
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- UK
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of Europe
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Asia Pacific
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- China
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- India
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Japan
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- South Korea
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of Asia Pacific
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Latin America
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- Brazil
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of South America
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Middle East & Africa (MEA)
- Chart on Market share by country 2021-2027 (%)
- Data Table on Market share by country 2021-2027(%)
- GCC Countries
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- South Africa
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
- Rest of MEA
- Exhibit: Chart on Market share 2021-2027 (%)
- Exhibit: Market size and forecast 2021-2027 ($ million)
KEY COMPANY PROFILES
- Competitive Landscape
- Total number of companies covered
- Exhibit: companies covered in the report, 2021
- Top companies market positioning
- Exhibit: company positioning matrix, 2021
- Top companies market Share
- Exhibit: Pie chart analysis on company market share, 2021(%)
- Total number of companies covered
Methodology
For the PD-1 And PD-L1 Inhibitors Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:
1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.
2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the PD-1 And PD-L1 Inhibitors Market.
3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.
4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.
Analyst Support
Customization Options
With the given market data, our dedicated team of analysts can offer you the following customization options are available for the PD-1 And PD-L1 Inhibitors Market:
Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.
Regional Analysis: Further analysis of the PD-1 And PD-L1 Inhibitors Market for additional countries.
Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.
Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.
Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.
Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.
Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.
Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.
USA (+1) 351-333-4748
